Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

By Shintaro Iwama, A. de Remigis, M. Callahan, S. Slovin, J. Wolchok, P. Caturegli. Science Translational Medicine, 2014

651 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a2fa27ed17df8d90060b476375bf7194e4e41b8d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Postow
2. C. Robert
3. E. Buchbinder
4. Anupam M. Desai
5. J. Wolchok

In Oncology

1. M. Postow
2. J. Wolchok
3. C. Robert
4. K. Kerr
5. K. Schindler
6. L. Connell
7. D. Page
8. J. Haanen

Citations in the corpus

• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review (2017, background): “Furthermore, tissue-related factors may also contribute to irAE, for example CTLA-4 expression is found in the pituitary accounting for the greater incidence of hypophysitis with CTLA-4 mAbs [64].”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Other immune cells may play a role in the development of irAEs, including B cells that secrete antibodies that may mediate toxicity [16, 17], granulocytes that secrete inflammatory mediators, and cytokines [16, 18].”
• Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “Serum pituitary auto-antibodies could be present [25].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Recently, in a murine model, low-level ectopic RNA and protein expression of CTLA4 on thyrotropin and prolactin secreting cells of the pituitary gland [30] was demonstrated.”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Recently, in a murine model, low-level ectopic RNA and protein expression of CTLA4 on thyrotropin and prolactin secreting cells of the pituitary gland [30] was demonstrated.”
• CTLA-4 and PD-1 Pathways (2016, background): “Hypophysitis is reported in about 2% to 4% of patients receiving ipilimumab but in <1% of patients receiving PD-1 inhibitors(51,54,55,69,80); however, this variation in incidence may not be related to differences in immune mechanism of action, but may be explained by ectopic expression of CTLA-4 in ”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2015, background): “Other immune cells may play a role in the development of irAEs, including B cells that secrete antibodies that may mediate toxicity [16, 17], granulocytes that secrete inflammatory mediators, and cytokines [16, 18].”